A Novel Slowly Self‐Emulsifying Drug Delivery System: Prolonged Systemic Exposure of Tacrolimus With Reduced Risks of Systemic Side Effects
Biopharmaceutics & Drug Disposition · 2026-04-10
DOI: 10.1002/bdd.70030 ↗At a glance
Journal article in Biopharmaceutics & Drug Disposition, published online on 2026-04-10. Written by Kohei Yamada and 7 co-authors. Institution: Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan. 31 references. Funded by: Japan Society for the Promotion of Science.
Abstract (original language)
This study aimed to design and characterize a new type of self‐emulsifying drug delivery system (SEDDS), slowly SEDDS (SL‐SEDDS), for long‐lasting systemic exposure of tacrolimus (TAC) with reduced nephrotoxicity. TAC‐loaded SL‐SEDDS (SL‐SEDDS/TAC) was prepared by semi‐solidifying TAC‐loaded SEDDS (SEDDS/TAC) composed of Capryol 90, Cremophor EL, and polyethylene glycol 400 with Geleol. SEDDS samples were evaluated regarding physicochemical and biopharmaceutical properties. Both SEDDS/TAC and SL‐SEDDS/TAC formed fine emulsions in water. The dissolution of SEDDS/TAC reached approximately 100% within the initial 30 min in simulated gastric fluid (SGF), and the SL‐SEDDS/TAC samples exhibited slower dissolution than SEDDS/TAC in a Geleol content‐dependent manner. SL‐SEDDS/TAC with a Geleol content of 17.5 wt% showed 25% dissolution in SGF for 2 h, followed by an additional 31% dissolution in simulated intestinal fluid for 10 h. The sample was selected as a favorable SL‐SEDDS/TAC for further studies because of its slow and continuous dissolution. Oral SEDDS/TAC and the selected SL‐SEDDS/TAC (10 mg‐TAC/kg) offered almost identical bioavailability of 18% and 19%, respectively, in rats. Compared with SEDDS/TAC, SL‐SEDDS/TAC achieved a 32% decrease in the maximum plasma concentration, a risk factor of nephrotoxicity, from 383 to 262 ng/mL with significantly prolonged mean residence time. In a rat model of acute kidney injury, SL‐SEDDS/TAC (10 mg‐TAC/kg/day, 3 days) attenuated the elevation of blood nitrogen urea by 33% compared to SEDDS/TAC, suggesting a reduction in nephrotoxic risks. SL‐SEDDS could be a promising dosage form to control oral absorption of TAC for effective and safe medication.
Subjects
Author keywords
Authors and institutions
- Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
- Catalent Japan K.K., Shizuoka, Japan.
ORCID profiles: Kohei Yamada, Hideyuki Sato, Satomi Onoue
Funding
- Japan Society for the Promotion of Science
Cite
APA
Yamada, K., Sonobe, K., Miura, A., Suzuki, T., Uchida, H., Katsuma, M., Sato, H., & Onoue, S. (2026). A Novel Slowly Self‐Emulsifying Drug Delivery System: Prolonged Systemic Exposure of Tacrolimus With Reduced Risks of Systemic Side Effects. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.70030
Vancouver
Yamada K, Sonobe K, Miura A, Suzuki T, Uchida H, Katsuma M, et al. A Novel Slowly Self‐Emulsifying Drug Delivery System: Prolonged Systemic Exposure of Tacrolimus With Reduced Risks of Systemic Side Effects. Biopharmaceutics & Drug Disposition. 2026. doi:10.1002/bdd.70030
BibTeX
@article{Yamada2026,
author = {Yamada, Kohei and Sonobe, Keiya and Miura, Akihisa and Suzuki, Toshinobu and Uchida, Hiroyuki and Katsuma, Masataka and Sato, Hideyuki and Onoue, Satomi},
title = {A Novel Slowly Self‐Emulsifying Drug Delivery System: Prolonged Systemic Exposure of Tacrolimus With Reduced Risks of Systemic Side Effects},
journal = {Biopharmaceutics & Drug Disposition},
year = {2026},
doi = {10.1002/bdd.70030}
}
EUVIMED